# cGMP-dependent protein kinase I as a new target against stroke

> **NIH NIH R01** · MASSACHUSETTS GENERAL HOSPITAL · 2020 · $353,950

## Abstract

The signaling pathways by which NO protects against stroke injury are mediated by soluble guanylyl
cyclase activation and cyclic guanosine monophosphate (
cGMP)
formation. However, the mechanisms of
downstream signaling from cGMP to smooth muscle cells (SMC) remain incompletely understood. The cGMP-
dependent protein kinase I (cGKI) is a key mediator of cGMP signaling. Our preliminary results indicate that
reperfusion of middle cerebral artery was attenuated and stroke injury was more pronounced in cGKI SMC
specific inducible conditional knockout mice than in wild-type mice, suggesting a protective role for cGKI in
SMC against cerebral reperfusion injury.
 The overall goal of this project is to identify the molecular mechanisms underlying the protective effect
of cGKI signaling in SMC against stroke injury. We will test the hypotheses that cGKI mediate the protective
effects of cGMP and that the protective effects of cGMP-cGKI signaling are SMC specific.
We will take advantage of mice with inducible
knockout of cGKI in
SMC
to specifically study the
contributions of SMC-dependent vascular mechanisms to the protective effects of cGMP against stroke.
Our
goals are (1) to determine the role of cGKI SMC-dependent mechanisms to the protective effect in stroke and
(2) to identify the molecular mechanisms underlying
the protective role of cGKI-SMC signaling
in stroke injury.
These results will make possible the development of new specific therapeutic approaches to stroke.
 HypothesiscGKI in smooth muscle cells protects against stroke.
 Aim 1: To determine the relevance and mechanism of cGKI-mediated signaling in SMC for
stroke protection. We will study whether deficiency of cGKI in SMC worsens stroke outcome in cGKI SMC-
specific knockout mice. We will compare stroke outcome in cGKI knockout mice and cGKI wild-type mice. We
will determine neurological deficit and infarct volume after occlusion and reperfusion of the middle cerebral
artery and compare cerebral blood flow at baseline and during ischemia and reperfusion.
 Aim 2: To study the role of cGKI of SMC in vascular reactivity. We will test whether cGKI deletion
in SMC impairs reactivity of isolated vessels, cerebral blood flow and autoregulation.
 Aim 3: To investigate the role of platelets and leukocytes in stroke injury of cGKI SMC deficient
mice. Platelets aggregation and accumulation of leukocytes within cerebral microvessels is critically involved in
stroke injury. We will study how cGKI deficiency in SMC affects the role of platelet aggregation and leukocytes
accumulation in stroke injury.
 We anticipate that studies described in this proposal will establish a new mouse model for stroke
studies and further our knowledge on the role of cGKI SMC signaling in the protection against stroke. These
results will be critical to provide the scientific foundation for the development of cGKI-elevating compounds as
therapeutic agents in stroke patients.

## Key facts

- **NIH application ID:** 9963403
- **Project number:** 5R01NS096237-05
- **Recipient organization:** MASSACHUSETTS GENERAL HOSPITAL
- **Principal Investigator:** Dmitriy Atochin
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $353,950
- **Award type:** 5
- **Project period:** 2016-09-15 → 2022-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9963403

## Citation

> US National Institutes of Health, RePORTER application 9963403, cGMP-dependent protein kinase I as a new target against stroke (5R01NS096237-05). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9963403. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*